RNA editing is a post-transcriptional process that alters the nucleotide sequence of RNA transcripts to generate transcriptome diversity. Among the various types of RNA editing, adenosine-to-inosine (A-to-I) RNA editing is the most frequent type of RNA editing in mammals. Adenosine deaminases acting on RNA (ADAR) enzymes, ADAR1 and ADAR2, convert adenosines in double-stranded RNA structures into inosines by hydrolytic deamination. Inosine forms a base pair with cytidine as if it were guanosine; therefore, the conversion may affect the amino acid sequence, splicing, microRNA targeting, and miRNA maturation. It became apparent that disrupted RNA editing or abnormal ADAR expression is associated with several diseases including cancer, neurological disorders, metabolic diseases, viral infections, and autoimmune disorders. The biological significance of RNA editing in pharmacokinetics/pharmacodynamics (PK/PD)-related genes is starting to be demonstrated. The authors conducted pioneering studies to reveal that RNA editing modulates drug metabolism potencies in the human liver, as well as the response of cancer cells to chemotherapy agents. Awareness of the importance of RNA editing in drug therapy is growing. This review summarizes the current knowledge on the RNA editing that affects the expression and function of drug response-related genes. Continuing studies on the RNA editing that regulates pharmacokinetics/pharmacodynamics would provide new beneficial information for personalized medicine.
Introduction
Gene regulation occurs at every step in the central dogma. In addition to regulatory mechanisms that act on DNA and proteins, eukaryotic RNA transcripts are subjected to various processing, such as alternative splicing, nucleotide modification and localization. Among such regulatory mechanisms, RNA editing refers to sequence alterations, including insertion, deletion or nucleotide conversion, that offer diversity in the transcriptome. Adenosine-to-inosine (A-to-I) RNA editing is a predominant form of RNA editing in mammals ( Fig. 1) (Nishikura, 2010) . In 1987, an enzymatic activity that causes the unwinding of doublestranded RNA (dsRNA) was discovered in Xenopus laevis oocytes and embryos (Bass & Weintraub, 1987) . Later, this reaction was found to be the hydrolytic deamination of adenosine to form inosine, i.e., A-to-I RNA editing, which is catalyzed by adenosine deaminase acting on RNA (ADAR) enzymes (Bass & Weintraub, 1988; Wagner, Smith, Cooperman, & Nishikura, 1989) . At that time, a limited number of RNA editing sites were discovered in the coding region of mRNA by comparing the sequences of genomic DNA and cDNA using Sanger sequencing (Sommer, Köhler, Sprengel, & Seeburg, 1991) . Within the past 10 years, the progress of next-generation sequencing technologies has enabled the high-throughput identification of 4.5 million A-to-I RNA editing sites, not only in the coding region but also in the non-coding region (Picardi, D'Erchia, Giudice, & Pesole, 2017) . Since the base-paring property of inosine is similar to that of guanosine, the conversion of nucleotides potentially affects gene function and expression, depending on the region where the editing event occurs. For genes associated with pharmacokinetics (PK) and pharmacodynamics (PD), the roles of RNA editing have just started being studied. The purpose of this review is to outline recent findings on the role of RNA editing of PK/PD-related genes and its potential pharmacotherapeutic implications.
ADAR enzymes
ADAR enzymes convert the adenosines in dsRNA structures into inosines by hydrolytic deamination at the C6 position (Gerber, O'Connell, & Keller, 1997; Kim, Wang, Sanford, Zeng, & Nishikura, 1994) . A highly conserved deaminase domain in the C-terminal region and dsRNA-binding domains in the N-terminal region of ADARs catalyze this reaction (Nishikura, 2016) . In the ADAR family in vertebrates, there are three members, ADAR1, ADAR2, and ADAR3 (also called ADAR, ADARB1, and ADARB2, respectively) (Bass et al., 1997) . The ADAR1 gene encodes two isoforms, ADAR1 p110 (110 kDa protein) and ADAR1 p150 (150 kDa protein), using different transcription initiation sites and start codons. The former is constitutively expressed and is localized in the nucleus whereas the expression of the latter is induced by interferon and exists in both the nucleus and the cytoplasm (Desterro et al., 2003; Patterson & Samuel, 1995) . ADAR2, which is also a ubiquitous form, is highly expressed in the brain and is localized in nucleus (Melcher et al., 1996b) . The expression of ADAR3 is limited to the brain (Chen et al., 2000; Melcher et al., 1996b) . ADAR1 (Kim et al., 1994) and ADAR2 (Melcher et al., 1996a) have A-to-I RNA editing ability whereas ADAR3 does not show editing activity (Chen et al., 2000; Herbert et al., 1997; Melcher et al., 1996b) . For ADAR1 and ADAR2, homodimerization is required to exert their editing activities (Cho et al., 2003; Poulsen et al., 2006; Valente & Nishikura, 2007) . Cho et al. (2003) have reported that ADAR3 is unable to homodimerize, which may account for its lack of editing activity. Although there is no strict sequence specificity for A-to-I editing, the surrounding nucleotides have some influence on recognition by ADARs. ADAR1 has a 5′ neighbor preference (A = U N C N G), but no apparent 3′ neighbor preference (Riedmann, Schopoff, Hartner, & Jantsch, 2008) . The 5′ neighbor preference of ADAR2 (A ≈ U N C = G) is similar to that of ADAR1 whereas ADAR2 has a 3′ neighbor preference (U = G N C = A) (Polson & Bass, 1994) . Some nucleotides are edited by either ADAR1 or ADAR2, and the others can be edited by both enzymes (Hartner et al., 2004; Lehmann & Bass, 2000) .
Mice genetically lacking either ADAR1 or ADAR2 were generated. It has been reported that the ADAR1-null mouse dies with numerous tissue failures at the embryogenesis stages (E11.5-12.5) (Wang et al., 2004) , and the ADAR2-null mouse dies with epileptic seizures at postnatal day 20 (Higuchi et al., 2000) , suggesting that ADAR proteins are indispensable for life.
Functional significance of A-to-I RNA editing of coding genes and miRNAs
Following the conversion of adenosine into inosine, the nucleotide is interpreted as a guanosine, leading to a series of functional consequences depending on the site of A-to-I editing ( Fig. 2) (Zipeto, Jiang, Melese, & Jamieson, 2015) . Editing in the coding region of pre-mRNA may change the genetic code, resulting in a change in the amino acid sequence. Editing in the intron may affect splicing by generating or deleting alternative splice sites. The editing events within the 3′-untranslated region (3′-UTR) have the potential to create or destroy the binding site of microRNAs (miRNAs) (Borchert et al., 2009; Deffit & Hundley, 2016; Farajollahi & Maas, 2010) . miRNAs are short (~22-nucleotide), endogenous non-coding RNAs that regulate gene expression at the post-transcriptional level via base pairing with the target mRNA, resulting in gene silencing by either translational repression or mRNA degradation (Bartel, 2004) . Nucleotides 2-8 at the 5′-end of the miRNA, called the seed sequence, are critical and sometimes sufficient for repressing the target translation (Lewis, Burge, & Bartel, 2005) . The biogenesis of miRNA is a multi-step process. miRNAs are transcribed in the nucleus by RNA polymerase II as long primary transcripts (pri-miRNAs) containing a stem-loop structure. The pri-miRNAs are subsequently cleaved into 70-100 nt precursors (pre-miRNAs) by the microprocessor complex, which is composed of the RNase III, Drosha and DiGeorge syndrome critical region 8 (DGCR8). After they are exported into the cytoplasm by exportin 5, pre-miRNAs undergo secondary cleavage by Dicer and TAR RNA binding protein (TRBP), leading to mature miRNA duplexes, and then they are unwound into the guide strand form of mature miRNAs. The passenger strand, named miRNA*, is usually degraded, but it is sometimes functional. The stem-loop structures of pri-miRNAs and pre-miRNAs are favorable targets for ADARs (Kawahara, Zinshteyn, Chendrimada, Shiekhattar, & Nishikura, 2007; Luciano, Mirsky, Vendetti, & Maas, 2004) . The A-to-I change in a miRNA transcript can alter its processing by changing the ability of Drosha and Dicer to bind to pri-miRNA and pre-miRNA, thereby affecting miRNA expression. In other cases, A-to-I editing of the miRNA seed sequence could change its target selection or binding efficiency, although editing frequency in this region is low (Alon et al., 2012; Ekdahl, Farahani, Behm, Lagergren, & Öhman, 2012; Vesely, Tauber, Sedlazeck, Haeseler, & Jantsch, 2012) . With the finding of miRNAs, RNA editing became recognized as a critically important regulator of gene expression.
In addition to A-to-I sequence change in miRNAs or their targets, ADAR regulates miRNA processing via an editing-independent mechanism (Nishikura, Sakurai, Ariyoshi, & Ota, 2013) . It has been reported that ADAR1 forms a complex with DGCR8 which is mutually exclusive with the DGCR8-Drosha complex, leading to suppression of processing of pri-miRNA to pre-miRNA (Chen et al., 2015; Nemlich et al., 2013) . Ota et al. (2013) revealed that ADAR1 forms a heterodimer with Dicer to function like TRBP, a Dicer's partner. ADAR1 promotes Dicer-dependent pre-miRNA cleavage, resulting the increase of generation of miRNAs. Thus, ADAR has a potential to modulate global miRNA synthesis.
Databases of RNA editing sites
Recent advances in next-generation sequencing enabled us to identify global RNA editing sites. RNA editing sites have been compiled in databases such as DARNED (http://darned.ucc.ie/, Kiran & Baranov, 2010; Kiran, O'Mahony, Sanjeev, & Baranov, 2013) , RADAR (http:// rnaedit.com/, Ramaswami & Li, 2014) , and REDIportal (http://srv00. recas.ba.infn.it/atlas/, Picardi et al., 2017) . According to RADAR, almost all of the editing sites (99.83%) are located in non-coding regions, including introns and UTR in coding genes as well as non-coding RNA molecules (Ramaswami & Li, 2016) . A limited number of genes are edited in the coding regions, and their effects on protein function have been demonstrated (Pinto, Cohen, & Levanon, 2014) . Despite the broad distribution of editing sites in the non-coding regions, their physiological and functional significances largely remain to be clarified. The databases can help us to search for editing sites that may have biological significance.
Diseases associated with RNA editing
Accumulating evidence has demonstrated that disrupted RNA editing or abnormal ADAR expression in humans is linked with several diseases, including cancer, neurological disorders, metabolic diseases, viral infections, and autoimmune disorders (Table 1) (Slotkin & Nishikura, 2013) . In this section, the studies on the RNA editing that is associated with a neurological disorder, cancers and a metabolic disease are summarized.
Neurological disorder
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that is characterized by the selective death of motor neurons. Although mutations of the superoxide dismutase gene have been found in 20% of familial ALS patients (Rosen et al., 1993) , the majority of ALS cases are sporadic. Glutamate receptor 2 (GluR2), a subunit of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, is the first example that was found to be subjected to A-to-I editing in mammals (Sommer et al., 1991) . The editing occurs in the coding region and causes an amino acid substitution, Q607R. This site is completely edited in neurons throughout life, starting in, from the embryonic stage onwards. Kawahara et al. (2004) found that its editing levels in the motor neurons from patients with sporadic ALS were lower than those in healthy subjects. Motor neurons with less edited receptors had increased Ca 2+ , which resulted in cell death (Higuchi et al., 2000) . Two research groups reported that the loss of editing of GluR2 is attributed to the decreased expression of ADAR2 (Aizawa et al., 2010; , although the reason behind the down-regulation of ADAR2 in ALS patients remains to be clarified. Hideyama et al. (2010) have generated a conditional knockout mouse whose motor neurons lack ADAR2. These mice prematurely died with a neuronal defect , but the restoration of ADAR2 could rescue them, indicating that the editing of GluR2 is crucial for neuronal survival (Yamashita et al., 2013) .
Interestingly, a research group reported that antidepressants, such as paroxetine and imipramine, have the potency to enhance the editing of GluR2 at the Q/R site by up-regulating ADAR2 expression (Sawada et al., 2009) . Therefore, such drugs may have the potential to treat sporadic ALS. In addition, the Q607R substitution changes the affinity toward the Joro spider toxin (JSTX) isolated from Nephila clavata, which is one of the most potent blockers of the AMPA receptor (Blaschke et al., 1993) . Non-edited GluR2 has a higher affinity toward sJSTX than edited GluR2 (Iino, Koike, Isa, & Ozawa, 1996; Savidge & Bristow, 1998) . Therefore, inhibitors that are specific to the non-edited receptor may be an additional tool for ALS therapy.
Cancers
Tumor initiation and progression are the processes characterized by cellular changes in proliferation, differentiation and survival. Some genes and non-coding RNAs are involved in these processes as oncogenes or tumor suppressor genes. In addition, the effects of somatic mutations on cancer progression are well studied. RNA editing was also been found to be dysregulated in human cancers (Galeano, Tomaselli, Locatelli, & Gallo, 2012) . Interestingly, ADARs differentially function as oncogenes or tumor suppressive genes, depending on the cancer type, to cause hyper-or hypo-editing. Here, we summarize the studies demonstrating the role of A-to-I editing in cancer biology Slotkin & Nishikura, 2013) .
Hepatocellular carcinoma (HCC) is the third most common cause of cancer related deaths in the world. Recent studies demonstrated that the dysregulation of ADARs in tumors, which causes bankrupted editing, underlies tumor progression (Chan et al., 2014; Chen et al., 2013) . Patients with up-regulated ADAR1 have an increased risk of liver cirrhosis, postoperative recurrence, and poor prognoses (Chan et al., 2014) . In that study, the authors found that the mRNA of antizyme inhibitor 1 (AZIN1) is edited by ADAR1, leading to an S367G amino acid substitution (from AGC [serine] to GGC [glycine] ). AZIN1 inhibits the antizyme-mediated degradation of cycle regulatory proteins, such as ornithine decarboxylase and cyclin D1 (Bercovich & Kahana, 2004; Coffino, 2001; Kahana, 2009; Newman et al., 2004) . The editing of AZIN1 mRNA resulted in the stabilization of AZIN1 protein and increased its binding to the antizymes to prevent the degradation of onco-proteins. Notably, the edited AZIN1 conferred a tumorigenic phenotype to HCC cells that presented as higher proliferation and invasive ability, indicating that ADAR1 functions as an oncogene by enhancing the activity of AZIN1. A recent study revealed that Ba/F3 cells (murine dependent pro-B cell line) stably expressing edited AZIN1 shows a higher resistance to BMS536924, an IGF-1R inhibitor, than the cells expressing non-edited AZIN1 (Han et al., 2015) . The authors found that the IC 50 value of chemotherapy agents, such as paclitaxel, irinotecan and topotecan, were correlated with the editing levels of AZIN1 in 740 cell lines from the Cancer Cell Line Encyclopedia (Barretina et al., 2012) , suggesting that RNA editing could modulate the sensitivity of cancer cells to the drug. Another study revealed that ADAR2 expression is elevated in HCC tissues and that ADAR2-mediated RNA editing of premiR-214 resulted in a decrease in the mature miR-214 level, leading to increased expression of its target Rab15, a member of the RAS oncogene family.
Melanoma is the most aggressive type of skin cancer. Shoshan et al. (2015) found that cyclic AMP-responsive element binding protein (CREB) negatively regulates ADAR1 expression and that ADAR1 inhibits melanoma tumor growth and metastasis. It has been reported that RNA editing by ADAR1 suppresses the maturation of pri-miR-455. The decrease in ADAR1 expression results in the decreased editing of primiR-455, an increased mature miR-455-5p level, and decreased levels of its target, the tumor suppressor cytoplasmic polyadenylation element-binding protein 1 (CPEB1) in melanoma progression.
Previous studies have revealed a decreased expression of ADAR2 in glioblastoma, which is the most aggressive type of brain cancer (Galeano et al., 2013; Ishiuchi et al., 2002; Maas, Patt, Schrey, & Rich, 2001) . The restoration of ADAR2 in glioblastoma cells resulted in decreased proliferation and migration in vitro. As the biological mechanism, it has been reported that the phosphatase CDC14B, which regulates Skp2/p21/p27 and is involved in glioblastoma growth, is a target of ADAR2 (Galeano et al., 2013) . Onco-miRNAs, pri-miR-21 and primiR-221/222 are edited by ADAR2, leading to a decrease in their mature miRNA levels (Tomaselli et al., 2015) . The seed sequence of miR-376* is edited by ADAR2, but the editing is reduced in glioblastoma. Since nonedited miR-376* directly represses RAP2A (a member of RAS family) expression, the increase in the non-edited miR-376* level by a decreased editing level in glioblastoma facilitates the down-regulation of RAP2A (Choudhury et al., 2012) . Interestingly, it has been revealed that hypoediting of the coding region of GluR2 increases Ca 2+ influx, leading to the promotion of glioblastoma growth (Ishiuchi et al., 2002) . Thus, these studies indicate the essential role of ADAR2 in glioblastoma, with ADAR2 acting on multiple targets that contribute to cancer progression. The biological significance of RNA editing in cancer is not fully understood. Current knowledge of ADAR's impact on human cancer development and progression may provide new ideas for developing drugs for cancer therapy. A study demonstrated that 2′-O-methyl/locked nucleic acid mixmer antisense oligonucleotides against the target region of ADAR can be potent and selective inhibitors of RNA editing (Mizrahi, Schirle, & Beal, 2013) . Site-selective editing inhibitors could have therapeutic potential in cancers, which are characterized by hyper-editing at specific sites.
Metabolic disease
Type 2 diabetes mellitus (T2DM) is a metabolic disease characterized by the abnormal secretion and uptake of insulin. The glucose-stimulated secretion of insulin from pancreatic β-cells plays a pivotal role in the pathology of T2DM (Ashcroft & Rorsman, 2012) . It has been revealed that ADAR2 expression in pancreatic β-cells is up-regulated by glucose stimulation via the c-Jun amino-terminal kinase-1 pathway (Gan et al., 2006; Yang et al., 2012) . Another study demonstrated that the knockdown of ADAR2 impairs the secretion of insulin via glucose stimulation, suggesting that ADAR2 is required for insulin secretion by the pancreatic β-cells (Yang et al., 2010) . Although the responsible target(s) of ADAR2 for insulin secretion has not been uncovered, ADAR2-knockdowned β-cells exhibited a lower expression of two key molecules, Munc18-1 and synaptotamin-7, that are involved in vesicle exocytosis (Yang et al., 2010) . Further studies are required to disclose the mechanism in which ADAR2 is associated with the glucose-stimulated insulin secretion in pancreatic β-cells.
6. RNA editing of human AhR, which modulates PK As mentioned above, the roles of RNA editing in human diseases is becoming clear. However, the significance of RNA editing of the mRNAs that regulate drug responses is largely unknown. Recently, we found that there is a large inter-individual difference (220-fold) in ADAR1 protein expression (whereas ADAR2 was not detected) in human livers (Nakano et al., 2016) , which is the principal tissue of drug metabolism, indicating the possibility that interindividual differences in ADAR expression and RNA editing levels may affect the expression or function of drug metabolism-related genes.
In RADAR, many PK-related genes, including drug-metabolism enzymes, drug transporters and transcriptional factors, are registered as Gallo, Farace, and Michienzi (2009) mRNAs that are subjected to RNA editing (Table 2) . Almost all of the RNA editing sites are located in non-coding regions, such as introns and 3′-UTR, suggesting a possibility that the RNA editing events may affect the splicing or expression of the concerned genes. However, the biological significance of their RNA editing is not fully understood. Recently, we demonstrated the first evidence of the impact of RNA editing on the expression of drug-metabolism enzymes, which is described as follows. AhR is a ligand-activated transcription factor that regulates the expression of xenobiotic-metabolizing enzymes, including CYP1A1, CYP1A2, CYP1B1, UDP-glucuronosyltransferase, glutathione S-transferase (Ramadoss, Marcus, & Perdew, 2005) . We found that there are 38 edited sites in the 3′-UTR of AhR mRNA in the human liver. ADAR1 is responsible for their editing, and ADAR1-mediated RNA editing negatively regulates AhR expression in human liver cells (Nakano et al., 2016) (Fig.  3) . Interestingly, the down-regulation of the AhR attenuated 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated induction of CYP1A1, a downstream gene of AhR, suggests that RNA editing affects the expression of P450s. For the underlying mechanism of the negative regulation of AhR, we found that RNA editing creates the binding site of miR-378 in the 3′-UTR of AhR. In the human liver samples, a significant inverse association was observed between the miR-378 and AhR protein levels, suggesting that the RNA editing-dependent down-regulation of AhR by miR-378 contributes to the variability in the constitutive hepatic expression of AhR. This is the first evidence to reveal that A-to-I RNA editing modulates the potency of xenobiotic metabolism in the human liver.
RNA editing of human DHFR, which modulates PD
RNA editing can occur in the transcripts of a drug target, possibly affecting the drug response (Decher, Netter, & Streit, 2013; Streit & Decher, 2011) . We recently found a clinical significance to the RNA editing of dihydrofolate reductase (DHFR) expression.
DHFR is a key enzyme of folate metabolism. It catalyzes the reduction of dihydrofolate to form tetrahydrofolate using NADPH as a cofactor. Tetrahydrofolate is essential for the de novo synthesis of purine and thymidylate, which are required for DNA synthesis, cell growth and proliferation. Therefore, DHFR is a target of the chemotherapeutic agents methotrexate and pemetrexed (Fowler, 2001; Nazki, Sameer, & Ganaie, 2014; Schweitzer, Dicker, & Bertino, 1990) . The efficacy of methotrexate in cancer cells is often limited by the acquisition of resistance. As one of the mechanisms of methotrexate resistance, the overexpression of DHFR protein is recognized. In addition to the known mechanism, we recently found that DHFR expression in breast cancer is positively regulated by RNA editing via DHFR mRNA stabilization. For the underlying mechanism of the positive regulation of DHFR, we found that RNA editing destroys the binding sites of miR-25-3p and miR-125a-3p in the 3′-UTR of DHFR. (Nakano, Fukami, Gotoh, & Nakajima, 2017) (Fig. 4) . The up-regulation of DHFR enhanced cellular proliferation and resistance to methotrexate. The editing levels in breast cancer tissues were higher than in normal tissues, suggesting a possibility that hyper-editing of the DHFR transcript could be responsible for increased DHFR expression. ADAR1 may be a potential anti-tumor target for anti-folate compounds, including methotrexate. 
Potential effects of editing in miRNA on PK and PD
We and other research groups have revealed the impacts of miRNAmediated regulation on drug metabolism-related genes Nakajima & Yokoi, 2011) . For CYP enzymes, human CYP1A1 (Choi et al., 2012) , CYP1B1 (Tsuchiya, Nakajima, Takagi, Taniya, & Yokoi, 2006) , CYP2A6 , CYP2B6 (Jin et al., 2016) , CYP2C8 (Zhang, Surapureddi, Coulter, Ferguson, & Goldstein, 2012) , CYP2C9 (Rieger, Reutter, Hofmann, Schwab, & Zanger, 2015; , CYP2C19 Zhang et al., 2012) , CYP2E1 (Miao et al., 2016; Mohri et al., 2010; and CYP3A4 (Pan, Gao, & Yu, 2009; Shi et al., 2015; Wei et al., 2014) have been revealed to be regulated by miRNAs. Such accumulating evidence indicates that miRNA is an important determinant of drug efficacy and toxicity. However, it remains to be clarified how the expression of miRNAs that regulate PK/PD-related genes is regulated. As mentioned above, the RNA editing in miRNA molecules has the potential to change their expression and function. In Table 3 , miRNAs that regulate PK-related genes and have RNA editing sites in their pre-miRNA are summarized. To further elucidate the impact of RNA editing on PK/PD, the effects of the RNA editing of pre-miRNAs on the expression of PK/PD-related genes that are the targets of miRNAs should be evaluated.
Conclusions
At present, the critical roles of RNA editing in physiological processes and their involvement in human diseases are becoming clear. The significance of RNA editing in the research field of PK/PD has only recently started to become clear, and this post-transcriptional modulation could be an additional solid factor that causes intra-and inter-individual differences in drug response. The issues that would make it possible for RNA editing to become a part of pharmacotherapy are as follows: (1) Fig. 4 . The up-regulation of dihydrofolate reductase (DHFR) expression by RNA editing. The 3′-UTR of DHFR is edited by ADAR1, and the edited DHFR mRNA can escape from repression by miR-25-3p and miR-125a-3p, leading to an increase in DHFR expression in breast cancer cells with high ADAR1 expression. This mechanism affects cellular proliferation and resistance to methotrexate. Margaillan et al. (2015) , Wijayakumara et al. (2015) These pre-miRNAs are registered in RADAR (http://rnaedit.com/search/). a The numbering denotes the 5′ end of the pre-miRNA as +1.
The impact of RNA editing on the expression or function of PK-related genes should be examined, as the functional significance of RNA editing of the mRNAs shown in Table 2 Studies to uncover the roles of RNA editing of the genes associated with pharmacotherapy would also provide useful information for personalized medicine.
